Cipher Pharmaceuticals Stock Price Patterns
| CPH Stock | CAD 16.52 -0.04 -0.24% |
Momentum
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 2.892 | EPS Estimate Next Quarter 0.244 | EPS Estimate Current Year 1.007 | EPS Estimate Next Year 1.2015 | Wall Street Target Price 19.5333 |
Headline intensity for Cipher Pharmaceuticals is presented with corresponding price behavior. Attention signals are paired with price data to support contextual interpretation.
The sentiment module for Cipher Pharmaceuticals aggregates news and social attention for context. This module places attention patterns alongside recent price behavior for context.
Cipher Pharmaceuticals after-hype prediction price | C$ 16.57 |
Hype signals are presented as complementary context to forecasting, technicals, and analyst estimates. Earnings expectations and momentum indicators provide additional analytical dimensions.
Cipher |
The mean reversion effect in Cipher Pharmaceuticals is stronger when the initial deviation was driven by sentiment rather than fundamentals. Such deviations have sometimes corrected when the initial catalyst fades, though timing remains uncertain. The degree to which Cipher Pharmaceuticals' exhibits mean reversion depends on how efficiently the market prices new information.
After-Hype Price Density Analysis
Visualizing the full distribution of potential Cipher Pharmaceuticals outcomes discourages binary thinking about investments. The width and shape of Cipher Pharmaceuticals's distribution determine how often extreme deviations from the central forecast occur. The asymmetry in Cipher Pharmaceuticals' distribution is a key input for options pricing and risk management around Cipher Pharmaceuticals.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
Historical analysis of Cipher Pharmaceuticals reveals distinct patterns in how Cipher Pharmaceuticals' price responds to different news categories. Cipher Pharmaceuticals' after-hype downside and upside margins for the prediction period are 13.77 and 19.37, respectively. No fundamental valuation inputs are used in this model; it is a purely empirical approach for Cipher Pharmaceuticals.
Current Value
The after-hype framework applied to Cipher Pharmaceuticals assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. The objective is to separate event-driven enthusiasm from a more stable price path once the market absorbs the catalyst.
Price Outlook Analysis
When Cipher Pharmaceuticals' Stock price moves apart from earnings, non-data drivers such as fund flows and sentiment often explain the gap. The Stock price of Cipher Pharmaceuticals may mix real investor interest with speculative momentum. When hype drives Cipher Pharmaceuticals up, the resulting high price may offer a short-sale chance once momentum fades.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.19 | 2.80 | 0.07 | 0.02 | 5 Events | 2 Events | In 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
16.52 | 16.57 | 0.06 |
|
Hype Timeline
Cipher Pharmaceuticals is currently traded for 16.52on Toronto Exchange of Canada. The company has historical hype elasticity of -0.07, and average elasticity to hype of competition of -0.02. Cipher is forecasted to increase in value after the next headline, with the price projected to jump to 16.57 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is estimated to be 0.06%, whereas the daily expected return is currently at 0.19%. The volatility of related hype on Cipher Pharmaceuticals is about 3393.94%, with the expected price after the next announcement by competition of 16.50. The company reported revenue of 51.33 M. Net Income was 27.81 M with profit before overhead, payroll, taxes, and interest of 40.42 M. Assuming the 90-day trading horizon the next forecasted press release will be in 5 days. Use Cipher Pharmaceuticals Basic Forecasting Models to cross-verify projections for Cipher Pharmaceuticals.Related Hype Analysis
Tracking the hype elasticity of Cipher Pharmaceuticals' direct competitors quantifies cross-asset sentiment effects on Cipher Pharmaceuticals. High hype elasticity between Cipher Pharmaceuticals and a peer indicates a strong market linkage in sentiment response. The information ratio and semi-deviation metrics provide a risk-adjusted view of Cipher Pharmaceuticals' competitors. news-to-return efficiency.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| WEED | Canopy Growth Corp | -0.01 | 9 per month | 0.00 | -0.21 | 5.13 | -7.77 | 17.20 | |
| OGI | OrganiGram Holdings | 0.07 | 8 per month | 0.00 | -0.10 | 5.37 | -4.88 | 24.01 | |
| TSND | TerrAscend Corp | -0.07 | 12 per month | 0.00 | -0.02 | 16.47 | -9.89 | 58.33 | |
| ACB | Aurora Cannabis | -0.53 | 7 per month | 0.00 | -0.21 | 4.39 | -5.91 | 14.71 | |
| EDT | Spectral Med | -0.06 | 4 per month | 1.95 | 0.05 | 5.60 | -3.68 | 15.23 | |
| HITI | High Tide | -0.03 | 13 per month | 0.00 | -0.13 | 3.35 | -4.77 | 12.23 | |
| GUD | Knight Therapeutics | -0.03 | 10 per month | 1.06 | 0.15 | 2.11 | -1.74 | 8.61 | |
| FRX | Fennec Pharmaceuticals | 0.00 | 8 per month | 2.46 | 0.02 | 5.68 | -5.04 | 22.70 |
Cipher Pharmaceuticals Additional Predictive Modules
Forecasting Cipher Pharmaceuticals's price movement relies on structured analysis of indicator behavior, momentum signatures, and historical volatility patterns. Time-series models tend to perform better when fed clean, stationary data with consistent periodicity.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Sentiment Indicators & Methodology
Sentiment analysis for Cipher Pharmaceuticals evaluates news tone, positioning, and narrative momentum. Information velocity affects demand balance and participation. Cipher Pharmaceuticals has a market cap of 420.12 M, P/E of 21.55, ROE of 23.91%.
Reported values for Cipher Pharmaceuticals are derived from periodic company reporting and market reference feeds and then standardized for analysis. Refresh timing depends on source availability.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardMore Resources for Cipher Stock Analysis
Other Information on Investing in Cipher Stock
Financial ratios for Cipher Pharmaceuticals organize key financial data into structured relationships. This format maintains consistency across different reporting periods.